# Gubra A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/gubra). ## Overview Gubra A/S is a Danish techbio company founded in 2008 that focuses on peptide-based drug discovery and preclinical contract research. It operates through three business units: Biotech, CRO, and Ventures, combining internal therapeutic development with external research services and new company creation. ## Products & services • Peptide-based drug discovery and preclinical R&D • Biotech pipeline development and partnering • Preclinical contract research services (CRO) • AI-enabled peptide design platform (StreaMLine) • Venture creation and incubation - **Biotech pipeline** (40%) — Internal drug discovery and early clinical development of differentiated peptide therapeutics. - **CRO services** (50%) — Preclinical contract research studies and supporting scientific services for external customers. - **Partnered programs** (8%) — Out-licensed or partnered programs that generate milestones and other collaboration value. - **Ventures** (2%) — New company formation and incubation activities built around Gubra’s technology and science base. - Peptide-based drug discovery and preclinical R&D - Biotech pipeline development and partnering - Preclinical contract research services (CRO) - AI-enabled peptide design platform (StreaMLine) - Venture creation and incubation ## Customers Gubra serves pharmaceutical and biotech companies that need preclinical research, target validation, and early discovery support, while its Biotech unit ultimately targets partners and future commercial licensees for its therapeutic assets. The CRO business also supports smaller biotech customers, which are sensitive to funding conditions, and larger pharma groups seeking specialized peptide and translational expertise. - **Pharmaceutical partners** (primary) — Buy access to partnered peptide programs and development rights to advance them clinically and commercially. - **Biotech CRO customers** (primary) — Outsource preclinical studies, model work, and target validation to Gubra’s CRO platform. - **Smaller biotech customers** (secondary) — Use CRO services for cost-effective scientific execution when internal funding and infrastructure are constrained. - **Internal pipeline stakeholders** (secondary) — Indirect economic users of Gubra’s platforms and studies that support Biotech asset advancement. - Pharmaceutical companies buying early research and partner-ready assets - Biotech customers needing preclinical studies and translational support - Partners licensing peptide programs for further development - Smaller biotech firms using CRO services when internal capacity is limited - Customers in obesity and metabolic disease research programs ## Geography Gubra is headquartered in Denmark and operates from Hørsholm, where it is expanding laboratory capacity. Its customer base is global, with CRO services sold to international pharmaceutical and biotech clients and partnered development programs with large multinational companies. - Headquartered in Denmark, with key operations in Hørsholm - Laboratory infrastructure is centered at the Danish headquarters - CRO services are sold to customers worldwide - Partner programs involve global pharma counterparts - Geographic diversification is mainly through customers, not factories ## Strategy Gubra’s strategy is to advance differentiated peptide assets to clinical proof-of-concept, then partner them for broader development and commercialization. In parallel, it uses its CRO platform to generate recurring scientific revenue, validate hypotheses, and strengthen internal discovery capabilities, while Ventures extends the business model into new opportunities. - **Advance GUB-UCN2 and other obesity assets** (short-term) — Clinical proof-of-concept creates partnering optionality and long-term value in metabolic disease. - **Strengthen CRO growth platform** (short-term) — Recurring contract research revenue supports the business while also feeding internal scientific capabilities. - **Scale the peptide discovery platform** (medium-term) — Platform depth improves hit generation, optimization, and the probability of producing differentiated assets. - **Develop Ventures as an incubation pathway** (medium-term) — New ventures can broaden monetization and reduce dependence on any single asset or collaborator. - Advance assets to clinical proof-of-concept before partnering - Use CRO as a recurring revenue and discovery engine - Expand peptide platform capabilities and therapeutic modalities - Build Ventures to create new opportunities beyond the core pipeline - Increase laboratory capacity to support parallel programs ## Risks Gubra’s business depends on successful scientific execution, clinical development, and partner decisions, all of which are uncertain and can change program timing and economics. The CRO business is also exposed to biotech funding cycles and customer spending, while the broader company faces typical drug-discovery risks such as trial failure, regulatory delay, and difficulty converting preclinical promise into clinical value. - **Clinical development failure** [high] — Lead programs may not show sufficient efficacy, safety, or differentiation in human studies. - **Partner dependence** [high] — Out-licensed programs are controlled by partners, so timing and commercialization outcomes are outside Gubra’s direct control. - **CRO funding cyclicality** [medium] — Smaller biotech customers can reduce spending when capital markets are weak, lowering demand for preclinical services. - **Scientific and platform execution risk** [high] — Drug discovery depends on successful target selection, optimization, and translational validation. - Clinical trial failure could reduce value of lead assets - Partner programs depend on third-party development decisions - CRO demand is tied to biotech funding and pharma R&D budgets - Peptide discovery is uncertain and may not yield viable products - Scaling parallel programs requires specialized talent and infrastructure ## Accounting Gubra’s revenue mix includes CRO service revenue and collaboration-related biotech revenue, so the timing of recognition can differ across contracts, milestones, and study completion. The company also has judgment-heavy areas such as capitalization versus expensing of development activity, valuation of partner-related milestone income, and potential intangible asset or investment valuation in the Ventures model. - **Revenue recognition timing** — Can cause lumpy reported revenue - **Development cost accounting** — Impacts EBITDA and balance sheet assets - **Fair value measurement** — Can create non-cash gains or losses - **Impairment assessment** — May reduce carrying value of assets - CRO revenue recognition depends on study progress and contract terms - Partner milestones can create lumpy biotech revenue timing - Development spending and capitalization judgments affect reported R&D - Ventures may involve fair value estimates for new investments - Impairment risk exists for capitalized projects and strategic holdings --- *Last updated: 2026-10-24T15:09:09.461858+00:00*